Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

SIMPLE SUMMARY: Therapeutic antibodies are an integral part of treatment regimens for metastasized colorectal cancer. In KRAS wildtype tumors both bevacizumab and cetuximab are active. While bevacizumab has previously been shown to induce tumor hypoxia, we here report that EGFR inhibition by cetuxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Urban, Hans, Maurer, Gabriele D., Luger, Anna-Luisa, Lorenz, Nadja I., Sauer, Benedikt, Stroh, Christopher, Trojan, Jörg, Mittelbronn, Michel, Steinbach, Joachim P., Harter, Patrick N., Ronellenfitsch, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589936/
https://www.ncbi.nlm.nih.gov/pubmed/33092032
http://dx.doi.org/10.3390/cancers12103050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589936/
https://www.ncbi.nlm.nih.gov/pubmed/33092032
http://dx.doi.org/10.3390/cancers12103050

Ejemplares similares